倍他米松磷酸盐降低产前激素疗效并与低出生体重相关:绵羊研究
该绵羊早产模型研究比较了单用低剂量醋酸倍他米松与标准剂量磷酸倍他米松+醋酸倍他米松的药效动力学。结果显示单用醋酸倍他米松组治疗反应率更高,而联合磷酸倍他米松组胎儿下丘脑-垂体-肾上腺轴抑制更重且出生体重更低。提示磷酸倍他米松产生的高浓度不额外改善肺成熟,反带来不利结局。
要点
- 单用低剂量醋酸倍他米松足以促进胎肺成熟。
- 联合磷酸倍他米松不改善肺成熟,反增加HPA轴抑制。
- 联合磷酸倍他米松与更低出生体重相关。
核心结论
- 单用醋酸倍他米松的低剂量产前激素治疗足以实现胎肺成熟。
- 联合磷酸倍他米松产生的高母胎倍他米松浓度不额外改善肺成熟,反与更重HPA轴抑制、更低治疗反应率和更低出生体重相关。
研究设计与样本
- 采用已建立的绵羊早产模型,孕122±1天(足月150天)单胎母羊随机分组。
- 三组:生理盐水对照组(n=12)、磷酸倍他米松+醋酸倍他米松组(n=12,0.25 mg/kg,间隔24小时肌注2次)、醋酸倍他米松组(n=11,0.125 mg/kg,间隔24小时肌注2次)。
主要发现
- 与盐水对照组相比,两个产前激素治疗组均显著改善肺生理反应(血气与通气数据)并呈现功能成熟的生化特征(mRNA和表面活性蛋白检测)。
- 醋酸倍他米松组治疗反应率显著高于磷酸倍他米松+醋酸倍他米松组。
- 生理结果与表面活性蛋白A量强相关。
- 磷酸倍他米松+醋酸倍他米松组出生体重更低,胎儿HPA轴抑制程度更重。
关键数值与推荐
- 早产羔羊按30分钟通气时PaCO2超过盐水对照组均值2个标准差以上定义为无反应者。
- 磷酸倍他米松+醋酸倍他米松剂量为0.25 mg/kg,间隔24小时肌注2次;醋酸倍他米松剂量为0.125 mg/kg,间隔24小时肌注2次。
临床怎么用
- 提示临床可探索避免高母胎倍他米松暴露的持续低剂量产前激素治疗方案。
- 联合磷酸倍他米松可能不增加肺成熟获益,且与不良出生结局相关,需谨慎评估。
局限性
- 本研究为绵羊动物模型,结果不能直接外推至人类临床实践。
- 治疗反应判定采用任意截断值(盐水对照组均值±2SD)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antenatal corticosteroid therapy is a standard of care for women at imminent risk of preterm labor. However, the optimal (maximum benefit and minimal risk of side effects) antenatal corticosteroid dosing strategy remains unclear. Although conveying overall benefit when given to the right patient at the right time, antenatal corticosteroid treatment efficacy is highly variable and is not risk-free. Building on earlier findings, we hypothesized that when administered in combination with slow-release betamethasone acetate, betamethasone phosphate and the high maternal-fetal betamethasone concentrations it generates are redundant for fetal lung maturation. OBJECTIVE: Using an established sheep model of prematurity and postnatal ventilation of the preterm lamb, we aimed to compare the pharmacodynamic effects of low-dosage treatment with betamethasone acetate only against a standard dosage of betamethasone phosphate and betamethasone acetate as recommended by the American College of Obstetricians and Gynecologists for women at risk of imminent preterm delivery between 24 0/7 and 35 6/7 weeks' gestation. STUDY DESIGN: Ewes carrying a single fetus at 122±1 days' gestation (term=150 days) were randomized to receive either (1) maternal intramuscular injections of sterile saline (the saline negative control group, n=12), (2) 2 maternal intramuscular injections of 0.25 mg/kg betamethasone phosphate+betamethasone acetate administered at 24-hour dosing intervals (the betamethasone phosphate+betamethasone acetate group, n=12); or (3) 2 maternal intramuscular injections of 0.125 mg/kg betamethasone acetate administered at 24-hour dosing intervals (the betamethasone acetate group, n=11). The fetuses were surgically delivered 48 hours after treatment initiation and ventilated for 30 minutes to determine functional lung maturation. The fetuses were euthanized after ventilation, and the lungs were collected for analysis using quantitative polymerase chain reaction and Western blot assays. Fetal plasma adrenocorticotropic hormone levels were measured in the cord blood samples taken at delivery. RESULTS: Preterm lambs were defined as either antenatal corticosteroid treatment responders or nonresponders using an arbitrary cutoff, being a PaCO2 level at 30 minutes of ventilation being more extreme than 2 standard deviations from the mean value of the normally distributed saline control group values. Compared with the animals in the saline control group, the animals in the antenatal corticosteroid treatment groups showed significantly improved lung physiological responses (blood gas and ventilation data) and had a biochemical signature (messenger RNA and surfactant protein assays) consistent with functional maturation. However, the betamethasone acetate group had a significantly higher treatment response rate than the betamethasone phosphate+betamethasone acetate group. These physiological results were strongly correlated to the amount of surfactant protein A. Birthweight was lower in the betamethasone phosphate+betamethasone acetate group and the fetal hypothalamic-pituitary-adrenal axis was suppressed to a greater extent in the betamethasone phosphate+betamethasone acetate group. CONCLUSION: Low-dosage antenatal corticosteroid therapy solely employing betamethasone acetate was sufficient for fetal lung maturation. The elevated maternal-fetal betamethasone concentrations associated with the coadministration of betamethasone phosphate did not in addition improve lung maturation but were associated with greater fetal hypothalamic-pituitary-adrenal axis suppression, a lower antenatal corticosteroid treatment response rate, and lower birthweight-outcomes not desirable in a clinical setting. These data warranted a clinical investigation of sustained low-dosage antenatal corticosteroid treatments that avoid high maternal-fetal betamethasone exposures.
引用
- Takahashi T, Fee EL, Takahashi Y, et al. Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birthweights when administered to pregnant sheep in combination with betamethasone acetate. Am J Obstet Gynecol. 2021. PMID: 34626553. doi:10.1016/j.ajog.2021.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。